港股创新药包揽QDII涨幅榜 据Wind数据统计，截至6月2日，全市场310只QDII基金中，有256只产品年内净值增长，占比82.6%。其中有37只产品年内净值增长率超过30%，42只基金收益率超 过两成。 从历史来看，QDII基金业绩排名与投资主题高度相关，尤其是近几年，领跑的产品多为美股科技基金、黄金主题以及原油等大宗商品主题基金，但风水轮流转，年 内原油天然气、标普生物以及纳斯达克主题基金则多数告负。 相反，今年以来随着南下资金的涌入带动的估值抬升，投向港股的QDII产品表现更为亮眼，尤其是医药主题基金更是一骑绝尘，业绩排名前30的QDII几乎均重仓了 港股创新药板块。 以涨幅居首的汇添富香港优势精选为例，该基金年内已获得约71%的收益，从重仓股的风格来看，汇添富香港优势精选近三年来成为一只不折不扣的港股创新药主 题基金，在经历漫长的底部蛰伏后，该基金在年内终于"守得云开见月明"，包括荣昌生物、科伦博泰生物以及信达生物等重仓股的集体大涨，使得基金业绩遥遥领 先。 近期，创新药的行情被各种利好消息接连点火。 年内，"吃药"行情久别重逢，但与上一轮医药牛市不同，本轮涨幅亮眼的个股集中在创新药板块，且港股市 ...

Core Viewpoint - The company announced the presentation of innovative pipeline data at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, highlighting advancements in its drug candidates [1] Group 1: Pipeline Innovations - The company will present data on the anti-CCR8 antibody ICP-B05 (CM369) [1] - The company will showcase findings related to the BCL2 inhibitor mesutoclax (ICP-248) [1] - The company will also introduce updates on the pan-TRK inhibitor zurletrectinib (ICP-723) [1]

Group 1 - The Hong Kong stock market showed a positive trend in May, with the Hang Seng Index fluctuating between 22,058.30 and 23,917 points, driven by optimism following the US-China tariff reductions [1] - The US suspended a planned 24% tariff on Chinese goods, reducing overall tariffs from 145% to 30%, while China reciprocated with a 10% tariff on US goods [1] - The IPO market in Hong Kong saw a resurgence, with major listings like CATL raising over 30 billion RMB, marking a significant recovery from last year's downturn [1] Group 2 - The innovative drug sector remains strong, with companies like Three Life Pharmaceutical and Stone Pharmaceutical announcing significant collaborations, leading to stock price surges [2] - The shipping sector benefited from tariff reductions, with companies like Orient Overseas International and SF Express seeing positive market reactions [2] - The overall outlook for the Hong Kong stock market in June is less optimistic due to a lack of strong catalysts and an increase in bearish news [2] Group 3 - The US faces significant fiscal challenges, including a downgrade of its credit rating by Moody's and a projected budget deficit increase of approximately $2.7 trillion over the next decade [3] - A substantial amount of US debt is set to mature in June 2025, raising concerns about the government's ability to refinance these obligations [3] - US-China trade negotiations are stalled, with potential new regulations targeting Chinese companies, indicating ongoing geopolitical tensions [3] Group 4 - The Federal Reserve's decision on interest rate cuts in June will depend on economic data, with recent inflation indicators showing a slowdown [4] - OPEC+ is expected to discuss oil production increases, which could further influence market conditions [4] Group 5 - Geopolitical developments show some promise, with Russia and Ukraine set to hold peace talks, although a resolution remains distant [5] - Tensions between India and Pakistan continue, with ongoing conflicts affecting regional stability [5] Group 6 - The Lujiazui Forum in June is anticipated to announce significant financial policies, which could positively impact market sentiment [6] - Southbound capital inflows have reached historical highs, indicating strong investor interest in the Hong Kong market [6] Group 7 - The investment strategy for June focuses on exploring domestic demand potential, as the market's upward momentum is expected to be driven by internal factors rather than external [7] - The innovative drug sector is likely to attract continued investment, supported by recent business development collaborations [8] Group 8 - Companies like China Biologic Products and Innovent Biologics are positioned for growth due to their strong product pipelines and recent approvals [10][12] - Environmental companies like Conch Venture Holdings are facing challenges but are expected to improve profitability through operational efficiency [14][16] - Infrastructure firms like Anhui Expressway are benefiting from acquisitions and increased traffic, leading to significant profit growth [17][18] Group 9 - China Resources Power is leveraging its market position and operational efficiency to maintain profitability, with a focus on renewable energy expansion [19][20] - China Shipbuilding Industry Corporation is experiencing strong demand in the shipbuilding sector, with expectations for continued growth [22] Group 10 - Jitu Express is seeing robust growth in package volume, particularly in Southeast Asia, driven by increased e-commerce activity [23][24] - Tongcheng Travel is reporting strong revenue growth, particularly in its core OTA business, with expectations for continued performance improvement [26][27] Group 11 - Anta Sports is experiencing significant growth in brand revenue, supported by successful product launches and channel innovations [28][29] - Multi-Point Intelligence is focusing on digital transformation solutions for local retailers, positioning itself as a leading SaaS provider in the sector [30][31][32]

Group 1 - The Hong Kong stock market experienced a significant pullback on May 30, yet the innovative drug sector saw gains, with notable increases in stocks such as CSPC Pharmaceutical rising over 8% and others like Fosun Pharma and Zai Lab increasing over 5% [1] - The Hong Kong innovative drug ETF (159567) attracted over 200 million yuan in net inflows over the past 20 trading days, indicating high market interest [1] - The development of innovative drugs in China is driven by the transformation of generic drug companies and the emergence of biotech firms, supported by unmet clinical needs and the urgency of multinational pharmaceutical companies to fill their pipelines as they approach patent cliffs [1] Group 2 - The innovative drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends such as AI-enabled drug development and the international expansion of domestic innovative drugs [2] - The innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from both AI advancements and the introduction of new healthcare policies targeting high-priced innovative drugs [2] - The investment value of domestic innovative drug companies is increasingly highlighted in the current market environment, with recent sector pullbacks attributed more to external policy expectations rather than fundamental changes [2]

5月30日，港股市场低开低走，港股创新药板块逆势上涨。港股创新药指数成份股中，石药集团涨超 7%，复星医药、昭衍新药涨超4%，云顶新耀、先声药业涨超2%，泰格医药、诺诚健华、凯莱英涨超 1%。港股创新药ETF（159567）过去20个交易日获得超2亿元资金净流入，市场热度较高。 生物制药行业长期流传"双十"规律，即从新药研发开始到最终获批上市需要平均耗时十年，投入成本约 十亿美元，而实际成本往往数倍于此。除了周期长、成本高，制药还是一项高风险的事业，据业内估 计，全球新药研发的成功率仅在2%到15%之间。但人工智能拥有突破创新药"双十"限制的潜力，波士 顿咨询研究表示，AI生成的药物分子在I期临床试验中，成功率高达80%～90%，高于50%的历史平均水 平；而在II期临床试验中，成功率为40%，仍然位于历史区间上限。 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 中泰证券认为，创新药板块近期展现出强劲的投资价值，主要得益于三生制药与辉瑞 ...

Group 1 - The core point of the article highlights the performance and holdings of the Huatai Fuhua Medical Service Flexible Allocation Mixed A Fund, which has shown significant growth in its net value and returns over various time frames [1] - As of May 29, 2025, the fund's latest net value is 1.6630 yuan, reflecting a growth of 5.32% [1] - The fund's performance over the past month shows a return of 9.70%, ranking 234 out of 2329 in its category; over the past three months, it has achieved a return of 29.11%, ranking 6 out of 2319; and since the beginning of the year, it has returned 38.12%, ranking 13 out of 2306 [1] Group 2 - The top ten stock holdings of the fund account for a total of 64.17%, with significant positions in companies such as Heng Rui Pharmaceutical (10.23%), Kelun Pharmaceutical (9.09%), and Bai Li Tian Heng (8.94%) [1] - The fund was established on June 18, 2015, and as of March 31, 2025, it has a total asset size of 4.408 billion yuan [1] - The fund manager, Zhang Wei, has extensive experience in the pharmaceutical sector, having held various positions in research and fund management since 2021 [2]

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, allowing for investment in low-risk financial products while ensuring that the funds are not diverted from their intended projects [1][3][5]. Fund Management and Usage - The company has established a special account for managing raised funds, with all funds deposited into this account upon receipt [2]. - The total amount of raised funds for investment projects is approximately 277.88 million RMB [2]. Cash Management Details - The company will manage up to 1 billion RMB of temporarily idle raised funds, investing in low-risk products such as structured deposits and time deposits, with a maximum investment period of 12 months [1][3][4]. - The cash management decision is valid for 12 months from the board's approval date, and the 1 billion RMB can be used in a rolling manner [4]. Investment Purpose and Products - The objective of cash management is to enhance the efficiency of fund usage and increase company returns without affecting the ongoing investment projects [3][5]. - The company will strictly control risks and will not use the funds for pledging or securities investment [3][4]. Operational Impact - The cash management strategy will not impact the company's main business operations or the progress of investment projects, aiming to improve fund efficiency and shareholder returns [5][7]. - The company will adhere to relevant accounting standards for financial instruments in managing these funds [5]. Approval and Compliance - The board of directors approved the cash management plan on May 29, 2025, ensuring compliance with regulatory requirements [7][8]. - The sponsor institution has confirmed that the plan aligns with regulatory guidelines and does not conflict with the company's investment project implementation [8].

中国国际金融股份有限公司 关于诺诚健华医药有限公司 使用部分暂时闲置募集资金进行现金管理及以通知存款、协定存 款等方式存放募集资金的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为诺诚健 华医药有限公司（以下简称"诺诚健华"或"公司"）的保荐机构，根据《中华人民共 和国公司法》《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易 所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、行政法规、部门规 章及业务规则的要求，对诺诚健华使用部分暂时闲置募集资金进行现金管理及以通知存 款、协定存款等方式存放募集资金的事项进行了认真、审慎核查，具体情况如下： 一、募集资金基本情况 公司首次公开发行股票并在科创板上市的注册申请于 2022 年 7 月 15 日经中国证 券监督管理委员会同意（证监许可[2022]1524 号《关于同意诺诚健华医药有限公司首次 公开发行股票注册的批复》），公司据此公开发行了人民币普通股 264,648,217 股股票， 每股发行价格为人民币 11.03 元，募集 ...

| A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-019 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | 诺诚健华医药有限公司 关于使用部分暂时闲置募集资金进行现金管理及 以通知存款、协定存款等方式存放募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 5 月 29 日，诺诚健华医药有限公司（以下简称"公司"或"诺诚健 华"）召开董事会，审议通过了《使用部分暂时闲置募集资金进行现金管理及以 通知存款、协定存款等方式存放募集资金》的议案，同意公司在确保不影响募集 资金投资项目建设及募集资金使用安排，并有效控制风险的前提下，将最高不超 过 10 亿元人民币的暂时闲置募集资金进行现金管理，购买安全性高、流动性好 的低风险投资产品（包括但不限于结构性存款、定期存款、大额存单等），在董 事会审议通过之日起 12 个月内可进行该现金管理，且该 10 亿元人民币额度可循 环滚动使用；并同意公司以通知存款、协定 ...

Core Viewpoint - The recent high-value transaction involving the innovative drug SSGJ-707 by 3SBio and Pfizer highlights the growing trend of Chinese biopharmaceutical companies expanding into international markets, despite challenges in the global pharmaceutical environment [2][4]. Group 1: Transaction Details - Pfizer has made a non-refundable upfront payment of $1.25 billion (approximately 9 billion RMB) for the rights to SSGJ-707 outside of China, with potential milestone payments totaling up to $4.8 billion (approximately 34.5 billion RMB) and an additional $100 million for equity subscription [2]. - This transaction sets a record for the upfront payment for a Chinese innovative drug going overseas, indicating a significant shift in the landscape of biopharmaceutical transactions [4]. Group 2: Company Background - 3SBio, established in 1993, is a well-established pharmaceutical company that went public on NASDAQ in 2007 and later privatized before listing on the Hong Kong Stock Exchange in 2015 [3]. - The subsidiary involved in the transaction, 3SBio Guojian, was formerly known as CITIC Guojian and is recognized as one of the earliest companies in China to engage in antibody drug research and sales [3]. Group 3: Market Trends - The trend of Chinese innovative drug companies seeking international partnerships has been growing, with a nearly 40% increase in outbound business development (BD) transactions since 2022, projected to reach around 120 deals worth approximately $63 billion in 2024 [6]. - The stock prices of 3SBio and 3SBio Guojian have surged over 200% and 130%, respectively, following the announcement of this transaction, reflecting strong market interest in innovative drug development [4]. Group 4: Strategic Implications - The increasing trend of "going overseas" is reshaping the clinical research strategies of domestic innovative drug companies, with many now considering international transactions as a key part of their development plans [4]. - The shift from a "me too" model to a focus on first-in-class (FIC) drugs is evident, as domestic companies are increasingly competing head-to-head with multinational pharmaceutical firms [4][5].